Emanuele DAmico
Overview
Explore the profile of Emanuele DAmico including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
87
Citations
1024
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zanghi A, Greco A, Giancipoli E, Tumani H, Avolio C, DAmico E
J Neurol
. 2025 Jan;
272(2):109.
PMID: 39812684
Background: Multiple sclerosis (MS) involves a complex interplay between immune-mediated inflammation and neurodegeneration. Recent advances in biomarker research have provided new insights into the molecular underpinnings of MS, including ferritin,...
2.
Zanghi A, Fantozzi R, Foschi M, Signoriello E, Inglese M, Lus G, et al.
Ther Adv Neurol Disord
. 2025 Jan;
18():17562864241304212.
PMID: 39803327
Background: Characterizing Cladribine tablets prescription pattern in daily clinical practice is crucial for optimizing multiple sclerosis (MS) treatment. Objectives: To describe efficacy, safety profile and new disease-modifying therapy (DMT) prescriptions...
3.
Landi D, Bartolomeo S, Bovis F, Amato M, Bonavita S, Borriello G, et al.
Mult Scler
. 2024 Sep;
30(11-12):1503-1513.
PMID: 39263885
Background: Evidence on the impact of dimethyl fumarate (DMF) during pregnancy in women with multiple sclerosis (MS) is limited. Objectives: To investigate disease activity and pregnancy outcomes in a retrospective...
4.
Zanghi A, Di Filippo P, Avolio C, DAmico E
Mult Scler Relat Disord
. 2024 Aug;
90():105795.
PMID: 39151236
Alemtuzumab, a humanized anti-CD52 monoclonal antibody, is approved for treatment of highly active relapsing multiple sclerosis (MS) but requires vigilant post-treatment monitoring due to associated risks. The prescription of subsequent...
5.
Zanghi A, Di Filippo P, Avolio C, DAmico E
Curr Neuropharmacol
. 2024 Aug;
23(3):310-316.
PMID: 39150030
Background: The associations between Multiple Sclerosis (MS) and cardiovascular diseases, drawn from epidemiological studies, have attracted much attention in recent years. Materials And Methods: The present study employed a monocentric,...
6.
Paolicelli D, Borriello G, Clerici R, Colombo E, Croce D, DAmico E, et al.
Neurol Ther
. 2024 Aug;
13(5):1415-1430.
PMID: 39093539
Introduction: Multiple sclerosis (MS) is a chronic neurodegenerative disease that leads to impaired cognitive function and accumulation of disability, with significant socioeconomic burden. Serious unmet need in the context of...
7.
Zanghi A, Di Filippo P, Avolio C, DAmico E
Curr Neuropharmacol
. 2024 Jul;
23(1):36-57.
PMID: 38988152
Myeloid-Derived Suppressor Cells (MDSCs) are a heterogeneous population of immature myeloid cells that play important roles in maintaining immune homeostasis and regulating immune responses. MDSCs can be divided into two...
8.
Lal A, Foong Y, Sanfilippo P, Spelman T, Rath L, Levitz D, et al.
J Neurol
. 2024 Jun;
271(9):5813-5824.
PMID: 38935148
Background: The COVID-19 pandemic raised concern amongst clinicians that disease-modifying therapies (DMT), particularly anti-CD20 monoclonal antibodies (mAb) and fingolimod, could worsen COVID-19 in people with multiple sclerosis (pwMS). This study...
9.
Zanghi A, Borriello G, Bonavita S, Fantozzi R, Signoriello E, Barone S, et al.
J Neurol
. 2024 May;
271(7):4495-4502.
PMID: 38704488
Background: The management of Multiple Sclerosis (MS) has undergone transformative evolution with the introduction of high-efficacy disease-modifying therapies (DMTs), specifically anti-CD20 monoclonal antibodies, such as ocrelizumab (OCR) and ofatumumab (OFA)....
10.
Zanghi A, Ferraro D, Callari G, Valentino P, Granella F, Patti F, et al.
Curr Neuropharmacol
. 2023 Oct;
22(2):339-345.
PMID: 37876043
Background: The intervals between two courses of anti CD20 therapies in the COVID19 pandemic era provided the opportunity to individually delay therapy, known as extended interval dosing (EID). Methods: We...